Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease

27 Apr 2019

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Hemoglobinopathies and Related Disorders
Share to Prenatal Screening and Diagnostics

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 31039344
DOI: 10.1016/j.ejphar.2019.04.042

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia diseasePMID 31039344Read ↗

CRISPR Gene Therapy: A Promising One-Time Therapeutic Approach for Transfusion-Dependent β-Thalassemia—CRISPR-Cas9 Gene Editing for β-ThalassemiaSemantic proximity Read ↗

A Review of Gene Therapies for HemoglobinopathiesSemantic proximity Read ↗

CRISPR–Cas9-mediated gene editing of the BCL11A enhancer for pediatric β0/β0 transfusion-dependent β-thalassemiaSemantic proximity Read ↗

Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34+ HSPCs by CRISPR/Cas9 for the induction of fetal hemoglobin.Semantic proximity Read ↗

Combined approaches for increasing fetal hemoglobin (HbF) and de novo production of adult hemoglobin (HbA) in erythroid cells from β-thalassemia patients: treatment with HbF inducers and CRISPR-Cas9 based genome editingSemantic proximity Read ↗

Therapeutic promise of CRISPR-Cas9 gene editing in sickle cell disease and β-thalassemia: A current reviewSemantic proximity Read ↗

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-ThalassemiaSemantic proximity Read ↗

The Cas9 Hammer-and Sickle: A Challenge for Genome Editors.Semantic proximity Read ↗

Gene Editing for Inherited Red Blood Cell DiseasesSemantic proximity Read ↗

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-ThalassemiaSemantic proximity Read ↗

The Fetal-to-Adult Hemoglobin Switch — Mechanism and TherapySemantic proximity Read ↗

CRISPR-mediated gene modification of hematopoietic stem cells with beta-thalassemia IVS-1-110 mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.